About

Small Cell Lung Cancer (SCLC) poses a significant challenge in oncology, with limited treatment options and poor prognosis for patients, with a 5-year survival rate under 7%. It represents about 13%–15% of lung cancer cases; however, SCLC still lacks the benefit of personalized and effective therapies that have transformed outcomes in other types of cancer.

·       Elucidate the proteomic significance of SCLC subtypes

·       Identify novel targetable proteins and proteomic pathways

·       Determine the genetic mutation landscape

·       Reveal the biological efficacy of chemotherapeutic and  targeted agents

·       Gain insights into specific metastatic patterns of each subtype

·       Establish diagnostic, predictive, and prognostic biomarkers using blood-based and radiomic approaches

Understanding the molecular underpinnings of SCLC is critical for developing tailored therapeutic strategies and improving patient outcomes. Our project represents a collaborative effort among esteemed institutions, including Medizinische Universitaet Wien, Országos Korányi Pulmonológiai Intézet, Kineto Lab. Kft, Universitaetsklinikum Essen, Lunds Universitet, Rijksuniversiteit Groningen, and Treat4Life AB. By pooling our expertise and resources, we aim to achieve progress in SCLC research and ultimately translate findings into clinical benefits.